Protagonist Therapeutics, Inc (PTGX) is a publicly traded Healthcare sector company. As of October 3, 2026, PTGX trades at $140.18 with a market cap of $9.06B and a P/E ratio of 114.90. PTGX moved +0.63% today. Year to date, PTGX is +60.66%; over the trailing twelve months it is +115.54%. Its 52-week range spans $33.70 to $160.81. Analyst consensus is strong buy with an average price target of $167.00. Rallies surfaces PTGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
12 analysts cover PTGX: 0 strong buy, 12 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $167.00.
| Metric | Value |
|---|---|
| Price | $140.18 |
| Market Cap | $9.06B |
| P/E Ratio | 114.90 |
| EPS | $1.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $160.81 |
| 52-Week Low | $33.70 |
| Volume | 498.92K |
| Avg Volume | 0 |
| Revenue (TTM) | $281.99M |
| Net Income | $82.91M |
| Gross Margin | 0.00% |
12 analysts cover PTGX: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $167.00.